Heparin 100U/L for Prevention of PVC Complications

Sponsor
IRCCS Policlinico S. Matteo (Other)
Overall Status
Completed
CT.gov ID
NCT01131754
Collaborator
(none)
214
1
2
27
7.9

Study Details

Study Description

Brief Summary

Flushes with saline solution are used for maintaining patency of peripheral intermittent intravenous catheters in many institution based on the results of previous studies showing that 10 U heparin/mL is not better than saline in this respect. The latest meta-analysis investigated also safety and efficacy of heparin concentrations of 100 U/ml used as an intermittent flush, but no firm conclusion was reached because of limitations of the few available studies.

Condition or Disease Intervention/Treatment Phase
  • Other: heparin 100U/L flushes
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
214 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
STUDIO CLINICO RANDOMIZZATO SULL'UTILIZZO DI EPARINA PER LA PROFILASSI DELLA TROMBOFLEBITE DA CATETERE VENOSO PERIFERICO
Study Start Date :
Jun 1, 2007
Actual Primary Completion Date :
Aug 1, 2009
Actual Study Completion Date :
Sep 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: Heparin sol 100U/L

peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.

Other: heparin 100U/L flushes
peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.

Active Comparator: saline

peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.

Other: heparin 100U/L flushes
peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.

Outcome Measures

Primary Outcome Measures

  1. Phlebitis or Occlusion []

    Phlebitis is defined as the presence of two or more symptoms/signs among pain, tenderness, warmth, erythema, swelling, or a palpable cord (score of ≥ 2 according to the Visual Infusion Phlebitis Score). Occlusion is defined as resistance to flushing as evidenced by the inability to administer 1 ml of flushing solution within 30 seconds.

Secondary Outcome Measures

  1. Ecchymosis []

    Ecchymosis is defined as a purple discoloration of the skin around the catheter insertion site larger than 1 cm.

  2. Heparin induced thrombocytopenia []

    Heparin induced thrombocytopenia is defined as a fall in platelet count > 50% of baseline value without any alternative explanation. To detect this phenomenon, platelet count is to be performed at baseline and, subsequently, every 5 days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • requiring i.v. therapy for an expected duration longer than five days

  • admitted to the 3rd medical ward of IRCCS Policlinico San Matteo

Exclusion Criteria:
  • bleeding tendency

  • platelet count less than 100 x 109/L

  • coagulation defects

  • previous adverse reaction to heparin

  • programmed cytotoxic therapy

  • inability to give an informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medicina 3 - IRCCS Policlinico San Matteo Pavia Italy 27100

Sponsors and Collaborators

  • IRCCS Policlinico S. Matteo

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01131754
Other Study ID Numbers:
  • EPA 2007
  • 2007-001347-21
First Posted:
May 27, 2010
Last Update Posted:
Jun 15, 2010
Last Verified:
Feb 1, 2007
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 15, 2010